TLDR: Biophta, a Paris-based preclinical biotech company, raised €6.5M in seed funding to accelerate trials for treating glaucoma and macular edema. Founded by experienced professionals, the company has developed an innovative technology for treating eye diseases.
Biophta, a preclinical biotech company in Paris, secured €6.5M in seed funding to advance their research and development efforts. The funding round was led by UI Investissement, Elaia, and GO Capital, with participation from Unither Pharmaceuticals and HTL Biotechnology.
The company plans to use the funds to further develop their technology for the treatment of eye diseases, specifically targeting glaucoma and macular edema, the leading causes of blindness. Biophta’s founders, Jean Cuiné and Jean Garrec, have over 40 years of experience in ophthalmology and drug development, making them well-equipped to drive the company’s success.
Biophta has developed a new standard of care for ocular diseases based on their “thiomer” biopolymers technological platform. Their ophthalmic insert, which transforms into a hydrogel pellet when placed on the eye, delivers a continuous and controlled low dose of drug for 7 days without moving. This innovative approach has the potential to revolutionize the treatment of eye diseases.
